Homo-harringtonine (HHT) – A highly effective drug against coronaviruses and the potential for large-scale clinical applications

Haijun Wen, Pei Lin, Gongxun Zhong, Zhichao Xu, Lei Shuai, Zhiyuan Wen, Chong Wang, Xue Cao, Wenbin He, Jing Feng, Qichun Cai, Huajuan Ma, Sijin Wu, Guodong Wang, Xue-Mei Lyu, Feng‐Liang Liu, Yong‐Tang Zheng, Hui Zeng, Xionglei He, Hualan Chen, Fujie Zhang, Chung‐I WubioRxiv 2021 · DOI

TL;DR

This paper proposes Homo-harringtonine (HHT), an existing leukemia drug, as a potent and broadly effective antiviral against coronaviruses, including SARS-CoV-2. HHT works by inhibiting viral protein synthesis, and the study demonstrates its efficacy in clearing SARS-CoV-2 in mouse models and its safety in dogs via nebulization, suggesting a promising therapeutic strategy for current and future coronavirus outbreaks.

What Problem Does This Paper Address?

The COVID-19 pandemic highlighted the urgent need for effective and broadly applicable treatments against coronaviruses. While many drugs have been screened, this paper addresses the challenge of finding a treatment that is not only effective against SARS-CoV-2 but also has the potential for broad application against other coronaviruses, is readily available, and can be administered safely and efficiently. The authors propose a novel approach: instead of screening drugs and then understanding their mechanisms, they first identify a general weakness of coronaviruses and then search for existing drugs that target this weakness.

Methods

The study employed a multi-pronged approach:

  • Literature Review and Drug Screening: A survey of existing literature was conducted to identify drugs targeting the viral life cycle of coronaviruses. Criteria for promising candidates included rapid clearance of SARS-CoV-2 in animal models (>80% within a week) with no adverse effects, and ideally, FDA approval, availability, and low cost.
  • In Vitro Antiviral Assays: HHT's efficacy was tested against various coronaviruses, including SARS-CoV-2, PEDV, SADS-CoV, and PDCoV, in cell cultures to determine IC50 values (the concentration of drug required to inhibit viral replication by 50%).
  • In Vivo Antiviral Studies in Mouse Models: HHT was administered to mice infected with SARS-CoV-2 via different routes (intraperitoneal injection, intranasal dripping, or a combination) to assess viral clearance and potential toxicity. Viral load was measured using qPCR and PFU assays.
  • Safety and Toxicology Studies in Canine Models: Dogs were used to evaluate the safety of HHT delivered via nebulization, a potential method for large-scale clinical application. Various parameters including body weight, blood cell counts, and serum biochemistry were monitored.
  • Mechanism of Action Investigation: The paper discusses the known mechanism of HHT as an inhibitor of protein elongation, which is hypothesized to be a general weakness of coronaviruses due to their large polyproteins.

Datasets

Not explicitly discussed as datasets in the traditional machine learning sense. The study relies on:

  • Published Literature: Extensive review of existing research on coronaviruses and antiviral drugs.
  • Experimental Data: Data generated from in vitro cell culture experiments, in vivo mouse studies, and in vivo canine safety studies.
  • Viral Strains: Specific strains of SARS-CoV-2 (e.g., HRB26M, strain 107), PEDV, SADS-CoV, and PDCoV were used.
  • Cell Lines: Vero E6 cells, African green monkey kidney epithelial cells, and Porcine intestinal epithelial cell clone J2 were utilized.

Key Insights and Ideas

  • Coronaviruses Share a Common Weakness: The large size and concatenated nature of viral non-structural proteins (NSPs) represent a potential Achilles' heel for coronaviruses, as inhibiting their synthesis can broadly impact viral replication.
  • HHT as a Broad-Spectrum Antiviral: Homo-harringtonine (HHT), an existing leukemia drug, effectively inhibits the protein elongation process, making it a potent inhibitor of multiple coronaviruses, including SARS-CoV-2, at nanomolar concentrations.
  • Nebulization: A Promising Delivery Route: HHT delivered via nasal dripping in mice and nebulization in dogs demonstrated efficacy and safety, respectively. This suggests that nebulization could be a viable, non-invasive, and scalable method for delivering HHT directly to the respiratory tract, the primary site of coronavirus infection.
  • Repurposing Existing Drugs is Efficient: Leveraging an already approved drug like HHT significantly shortens the timeline for potential clinical application compared to developing entirely new compounds.

Key Results

  • In Vitro Efficacy: HHT demonstrated potent inhibition of various coronaviruses, with IC50 values generally around 100 nM and eradication achieved at < 1 µM.
  • In Vivo Efficacy in Mice: HHT administration in mice led to the clearance of SARS-CoV-2 within 3-4 days, particularly when delivered via intranasal dripping.
  • Safety in Dogs: Nebulization of HHT in dogs at doses significantly higher than anticipated for human treatment showed no adverse effects, indicating a favorable safety profile for this delivery method.
  • No Published Drug Met Criteria: The authors found no previously published drug that met their stringent criteria for SARS-CoV-2 clearance in animal models with no adverse effects.

Limitations and Future Work

  • Clinical Trial Status: While a clinical trial protocol was approved in Beijing, it could not be implemented due to a lack of patients. The authors are offering this protocol to other medical facilities.
  • Human Trial Data: The study primarily relies on animal models. While promising, direct human clinical trial data is still needed to confirm efficacy and safety in patients.
  • Long-Term Effects: While short-term safety was demonstrated in dogs, long-term effects of HHT nebulization in humans are not yet known.
  • Vaccination Context: The authors acknowledge the rapid development of vaccines but suggest HHT treatment as a complementary strategy, especially for future epidemics or for individuals who may not respond well to vaccines.
  • Delivery Optimization: Further research may be needed to optimize HHT nebulization protocols for human use, including particle size and dosage.

Summary updated

Abstract

Abstract In the search for treatment schemes of COVID-19, we start by examining the general weakness of coronaviruses and then identify approved drugs attacking that weakness. The approach, if successful, should identify drugs with a specific mechanism that is at least as effective as the best drugs proposed and are ready for clinical trials. All coronaviruses translate their non-structural proteins (∼16) in concatenation, resulting in a very large super-protein. Homo-harringtonine (HHT), which has been approved for the treatment of leukemia, blocks protein elongation very effectively. Hence, HHT can repress the replication of many coronaviruses at the nano-molar concentration. In two mouse models, HHT clears SARS-CoV-2 in 3 days, especially by nasal dripping of 40 ug per day. We also use dogs to confirm the safety of HHT delivered by nebulization. The nebulization scheme could be ready for large-scale applications at the onset of the next epidemics. For the current COVID-19, a clinical trial has been approved by the Ditan hospital of Beijing but could not be implemented for want of patients. The protocol is available to qualified medical facilities.
BibTeX
@misc{wen2021homo,
  author = {Haijun Wen and Pei Lin and Gongxun Zhong and Zhichao Xu and Lei Shuai and Zhiyuan Wen and Chong Wang and Xue Cao and Wenbin He and Jing Feng and Qichun Cai and Huajuan Ma and Sijin Wu and Guodong Wang and Xue-Mei Lyu and Feng‐Liang Liu and Yong‐Tang Zheng and Hui Zeng and Xionglei He and Hualan Chen and Fujie Zhang and Chung‐I Wu},
  title = {{Homo-harringtonine (HHT) – A highly effective drug against coronaviruses and the potential for large-scale clinical applications}},
  year = {2021},
  doi = {10.1101/2021.04.16.440104},
  howpublished = {bioRxiv},
}
Figure